iCAD to Report First Quarter 2023 Financial Results on May 15, 2023

3 years ago

NASHUA, N.H., May 01, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer…

Pathways to Cures are in Sight as MS Canada Hosts Annual Day on the Hill with Carnation Pinning

3 years ago

OTTAWA, May 01, 2023 (GLOBE NEWSWIRE) -- Dozens of representatives of MS Canada are fanning across Ottawa May 1st – May…

Bioxytran Interview at the Emerging Growth Conference

3 years ago

Wednesday, May 3, 2023 12:35 pm –1:05 pm ESTMedical/Scientific Community Reaction to Peer Reviewed ArticleBOSTON, MASSACHUSETTS, May 01, 2023 (GLOBE…

OrthoPediatrics Corp. Continues Leading Sponsorship at 2023 POSNA Annual Meeting

3 years ago

Establishes Longer-term Commitment as an Emerald SponsorWARSAW, Ind., May 01, 2023 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”)…

Immutep Receives Approval to Initiate INSIGHT-005 Trial Evaluating Eftilagimod Alpha and Anti-PD-L1 Therapy BAVENCIO®

3 years ago

Media Release Investigator-initiated study jointly funded with Merck KGaA, Darmstadt, Germany, will evaluate dual immuno-oncology (IO) combination of eftilagimod alpha…

Cognition Therapeutics Appoints John Doyle to the Role of Chief Financial Officer

3 years ago

PURCHASE, N.Y. , May 01, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), today announced the appointment of John…

Intellia Therapeutics Releases 2023 Corporate Responsibility Report Highlighting the Advancement of its Environmental, Social & Governance (ESG) Priorities

3 years ago

CAMBRIDGE, Mass., May 01, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on…

Marker Therapeutics Announces Comprehensive Non-Dilutive Agreement With CellReady™

3 years ago

Structured To Extend Marker’s Financial Runway Through Year-End 2025 Marker Announces Leadership Transition & Provides Update on Operational Strategy HOUSTON,…

Atsena Therapeutics Receives FDA Clearance of IND Application for ATSN-201, an Investigational Gene Therapy for the Treatment of X-linked Retinoschisis

3 years ago

ATSN-201 leverages AAV capsid that spreads laterally beyond subretinal injection site to facilitate safe delivery of RS1 to photoreceptors in…

TG Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results

3 years ago

First quarter 2023 BRIUMVI net sales of $7.8 million Over 400 BRIUMVI prescriptions in the first partial quarter from 165+…